ClinicalTrials.gg
RecruitingNCT06040268SWIFTARCUpdated Sep 22, 2025

Advair HFA in Healthy and HAPE Predisposed Subjects

A Phase 1/2 interventional study of Advair HFA and Placebo in Altitude Edema, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by University of Colorado, Denver · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Altitude Sickness with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Altitude Sickness · United States.

Planned enrollment
15th of 37
60 · median 33
Started
2023
with 5 others
Phase 1/2
Only one
of the 39
Registered
33rd of 39
by date
Lead sponsor
6 of 39
University of Colorado, Denver

Among the 39 studies in Altitude Sickness with a site in United States, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2023, is the only one in phase 1/2, and was the 33rd registered.

Altitude Sickness

216 studies on the registry are indexed under Altitude Sickness; 46 are open to participants now.

Browse Altitude Sickness studies →

Open to participants now

3 of the 39 studies in Altitude Sickness with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Altitude Sickness studies recruiting now, 4 (24%) set no upper age limit and 10 (59%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Altitude Sickness with a site in United States, or all of them as a file.
02

Study summary

The current protocol is composed of two studies. The first study is designed to carefully evaluate the safety of high-dose salmeterol/fluticasone (Advair HFA) versus placebo (hydrofluoroalkane, HFA) administration over 7 days, as well as the efficacy of the study drug to increase exercise performance, in healthy individuals exercising under hypoxic, simulated high-altitude conditions (Phase 1/2a study). The second study will examine sensitive measures of cardiopulmonary function using invasive cardiopulmonary testing, in both HAPE-sensitive and HAPE-resistant individuals, to assess the potential efficacy of salmeterol/fluticasone to prevent pulmonary edema and to enhance exercise capacity (Phase 2a) in these individuals.

Read the detailed description

Both Study 1 and Study 2 are double-blinded, randomized, placebo-controlled, two-period, crossover studies.

Study 1 (Phase 1/2a) is a Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover study examining safety and efficacy in healthy subjects dosed with salmeterol/fluticasone 126mcg/270mcg twice daily vs. placebo, for 7 days. Subjects will exercise under hypoxic conditions one time during each study period with the primary efficacy outcome being maximal oxygen uptake (VO2max), and secondary outcomes of arterial partial pressure of oxygen (PaO2), alveolar-arterial oxygen (Aa) gradient, and blood lactate levels. Continuous cardiac monitoring will occur during study drug dosing and for 5 days after drug discontinuation. ECGs and safety lab tests will be assessed at key intervals during drug dosing. A pause in enrollment will occur for a planned data and safety monitoring board (DSMB) safety analysis after four subjects have completed Study 1. There will also be a full review of safety data once Study 1 is complete prior to initiating Study 2.

Study 2 (Phase 2a) is a Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover study examining efficacy and safety in both healthy (HAPE-resistant) and HAPE-susceptible subjects dosed with salmeterol/fluticasone 126mcg/270mcg twice daily. Subjects will take study drug for two days prior to hypoxic exercise testing in each period of this study, then discontinue study drug when the exercise is completed. Efficacy assessments will include VO2 max (primary outcome), right heart catheter measurements, PaO2, A-a gradients, and blood lactate.

For both studies, investigators and subjects will be blinded to assignment group (order of study drug vs. placebo).

03

Conditions studied

  • Altitude Edema

Keywords

  • salmeterol
  • fluticasone
  • exercise performance
  • high altitude pulmonary edema
  • hypoxia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written signed prior to entry into the study.
  • Male or female age 18-50 years of age
  • ≥ 20 and \< 35 kg/m2
  • Agreement to comply with the study-required interventions and treatment during the full duration of the study.
  • In good health as determined by screening medical history, physical examination, vital signs (blood pressure, heart rate, respiratory rate and temperature), clinical laboratory tests (CBC, protime (PT) ()/partial thromboplastin time (PTT), thyroid stimulating hormone (TSH), Total , blood chemistries, urine drug screening), and a resting 12-lead with a 10 second rhythm strip.
  • Adequate peripheral venous access for IV insertion and blood sample collection (assessments will be made prior to undergoing further assessments).
  • HAPE-susceptible individuals (Study 2 only) must have had a medically documented (hospital admission or emergency room visit) HAPE episode characterized by noncardiogenic pulmonary edema and hypoxemia that occurred during high altitude travel in Colorado and must reside below 3,000 feet (unacclimatized individuals; non-Colorado residents).
  • HAPE-resistant individuals (Study 2 only) will have had no evidence of HAPE during high altitude travel in Colorado, and must reside below 3,000 feet (unacclimatized; often being travel partners of HAPE-susceptible subjects).
  • Healthy controls (Study 1 only) will all be Colorado residents.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in or has been enrolled in another clinical trial within the last 30 days (observational studies are acceptable).
  • Donation of any blood or plasma in the last month, or donation of > 500 milliliters (ml) of blood within the 3 months preceding study drug administration.
  • Female subjects of with positive serum pregnancy (beta human chorionic gonadotropin) test, who are breastfeeding, plan to become pregnant during the study, or decline to either be abstinent or use highly effective if they have sexual intercourse with a male partner (ie, oral contraceptives; contraceptive patches, implants, injections, and rings; intrauterine devices - both hormonally-impregnated and untreated devices) throughout the study and for at least 1 month after study completion;
  • Known history of impaired liver function
  • laboratory abnormalities (one retest is allowed at the discretion of the Investigator and Medical Monitor), defined as:

    • Impaired renal function as estimated \< 60 mL/min/1.73 m2) as estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening.(81)
    • Serum Potassium \< 3.2 millimolar (mM)
    • (AST) or alanine transaminase (ALT) > 2x upper reference limit
    • (INR) > 1.5
    • Fasting serum triglycerides > 500 mg/dL (lipemic serum affects assays)
    • TSH \< 0.5 or > 5 milliunits/Liter (mU/L)
    • \< 12.0 g/dL
    • > 2, unless consistent with Gilbert's disorder (indirect bilirubinemia)
    • count \< 100,000/µL
    • Any other abnormality deemed by the Investigator to exceed normal safety limits for this study or exclude subject participation.
  • Cardiovascular conditions:

    • Clinically significant abnormal at screening:

      ▪ Clinically significant abnormal ECG results including but not limited to complete left or right bundle branch block; other ventricular conduction block (except for incomplete bundle branch blocks, with a Q to R to S (QRS) duration \< 0.12 sec) ; 2nd degree or 3rd degree atrioventricular (AV) block; sustained ventricular arrhythmia; sustained atrial arrhythmia; two or more premature ventricular contractions (PVC) in a row; pattern of (S wave to T wave) ST segment elevation felt consistent with cardiac ischemia; or any condition deemed clinically significant by a study investigator

    • Any history of congenital or acquired long syndrome
    • Any history of uncorrected re-entrant supraventricular tachycardia, atrial fibrillation, sinus tachycardia (> 100 bpm at rest), or ventricular tachycardia.
    • Evidence of conduction abnormality including QTc prolongation on ECG, defined as > 450 msec for men and > 470 msec for women
    • Unstable angina pectoris, history of myocardial infarction (MI), (TIA) or stroke within 3 months prior to screening, or subjects who have ever undergone percutaneous coronary intervention or a coronary artery bypass or who are due to undergo these procedures at the time of screening, as evidence of atherosclerotic cardiovascular disease (ASCVD).
    • Functional Class I-IV congestive heart failure (any congestive heart failure)
    • Use of any blood thinner (e.g. novel oral anticoagulant, coumadin/warfarin). Use of aspirin is acceptable for study and will not need to be discontinued prior to involvement in the study. Use of a P2Y12 inhibitor (such as clopidogrel) is also not permitted due to bleeding risks.
    • Use of any phosphodiesterase-5 inhibitors (as prescribed medications or obtained by other means) such as sildenafil, tadalafil, or vardenafil (as they may enhance hypoxic exercise performance)
  • Infectious conditions:

    o Active Coronavirus Disease 2019 (COVID-19) or any viral upper respiratory infection suspected by symptoms and/or confirmed by nasal swab polymerase chain reaction (PCR) or rapid antigen within the past 30 days. Subjects will be screened for COVID-19 at study entry by nasal swab antigen test on day 0 regardless of symptoms. A subject with recent COVID-19 will be allowed to participate provided that the diagnosis was made more than 30 days previously, COVID-related symptoms have been absent for 20 or more days, and an antigen test on day 0 is negative.

  • Concomitant Medications:

    • Nonselective beta-blockers including propranolol, carvedilol, and labetalol (due to antagonization of beta-2 agonist effects)
    • Use of any inhaled or oral beta-2 receptor agonists, or oral theophylline
    • Non-potassium sparing diuretics (due to hypokalemia risks)
    • The use of any medication known to be a strong inhibitor or strong inducer of cytochrome P (CYP) 3A4 or 3A5 enzymes (cytochrome P450 isoenzymes) that metabolize salmeterol.(66) Also, any medication that has been reported to have a major or moderate interaction with salmeterol or fluticasone(82)
    • Use of monoamine oxidase inhibitors or tricyclic antidepressants within 2 weeks of screening
    • Prescription amphetamines or other sympathetic stimulants used for disorders such as narcolepsy, somnolence, or attention deficit disorder
  • History of claustrophobia or post traumatic stress disorder that would limit use of gas breathing masks or mouthpieces.
  • Essential tremor limiting handwriting, or any tremor requiring medication.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Advair HFA (salmeterol 126 ug/fluticasone 270 ug) twice daily for up to 7 days

    Participants will inhale salmeterol 126 ug and fluticasone 270 ug twice daily for up to 7 days

    Drug: Advair HFA

  • Placebo comparator
    Placebo

    Participants will inhale placebo (same puff number) twice daily for up to 7 days

    Drug: Placebo

Interventions

  • DrugAdvair HFA

    6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily

    Also known as: salmeterol and fluticasone in hydrofluoroalkane (HFA) propellant

  • DrugPlacebo

    HFA134a inhaler

    Also known as: HFA134a (hydrofluoroalkane 134a, same propellant as in Advair HFA)

06

What researchers measure

Primary outcomes

  1. VO2 max

    peak oxygen consumption with exercise

    Time frame: day 3 of treatment

Secondary outcomes

  1. Aa Gradient

    alveolar-arterial oxygen Gradient during peak hypoxic exercise

    Time frame: day 3 of treatment

  2. blood lactate

    peak arterial blood lactate during peak hypoxic exercise

    Time frame: day 3 of treatment

  3. nadir PaO2

    lowest arterial partial pressure of oxygen during peak hypoxic exercise

    Time frame: day 3 of treatment

  4. highest PaO2

    highest arterial partial pressure of oxygen during peak hypoxic exercise

    Time frame: day 3 of treatment

  5. MPAP

    highest mean pulmonary arterial pressure (MPAP) during hypoxic exercise

    Time frame: day 3 of treatment

  6. cardiac output

    highest cardiac output during hypoxic exercise

    Time frame: day 3 of treatment

Other outcomes

  1. Cardiac rhythm (symptomatic)

    Safety as measured by number of subjects with symptomatic ectopy/tachyarrhythmias on continuous cardiac monitoring

    Time frame: 7 days of treatment and 7 days of washout

  2. Cardiac rhythm (asymptomatic)

    Safety as measured by number of subjects with asymptomatic ectopy/tachyarrhythmias on continuous cardiac monitoring

    Time frame: 7 days of treatment and 7 days of washout

  3. Serum potassium

    Safety as measured by number of subjects with serum potassium \< 3.3

    Time frame: Up to 7 days of treatment

  4. QTc (Q to T time interval, rate corrected)

    Safety as measured by number of subjects with QTc interval prolongation \> 30 msec on 12-lead EKG

    Time frame: Up to 7 days of treatment

  5. Drug discontinuation

    Number of subjects with adverse event-related study drug discontinuation (compared to placebo)

    Time frame: up to 7 days of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 15, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06040268
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Dec 12, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 22, 2025

Study contacts

James P Maloney, MD
Contact
james.maloney@ucdenver.edu
3037246072
James P Maloney, MD
principal investigator · Univ. of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion